We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.37 | 0.57% | 65.15 | 65.01 | 65.45 | 65.56 | 64.34 | 64.78 | 7,187,226 | 00:22:58 |
From May 2019 to May 2024
By Michael Dabaie
Gilead Sciences Inc. (GILD) said its Kite subsidiary had positive findings from real-world use of Yescarta in relapsed or refractory large B-Cell lymphoma.
Kite and the Center for International Blood and Marrow Transplant Research unveiled the findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta in adult patients.
In the analysis, efficacy and safety of Yescarta were comparable to that observed in the ZUMA-1 trial, despite a larger proportion of older, more difficult-to-treat patients in the real-world setting, Gilead said.
Yescarta was approved by the U.S. Food and Drug Administration in 2017 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 09, 2019 15:28 ET (20:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
